Related Experiment Video
Updated: Aug 23, 2025
10:39
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
12.7K
Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA Vector
Luis A F Andrade1,2, Alice F Versiani3, Edel F Barbosa-Stancioli1
1Laboratory of Basic and Applied Virology, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.
Vaccines
|October 27, 2022
Summary
A new vaccine prototype targeting feline immunodeficiency virus subtype B (FIV-B) has been developed. Preclinical tests in mice show it effectively stimulates cellular and humoral immune responses, supporting further development for cat vaccination.
Area of Science:
- Veterinary Immunology
- Virology
- Vaccine Development
Background:
- Feline immunodeficiency virus (FIV) is a global retrovirus causing severe immunosuppression in cats.
- Current vaccines are ineffective against FIV subtype B (FIV-B), a prevalent strain worldwide.
- There is a critical need for a FIV-B vaccine to protect domestic and wild felids.
Purpose of the Study:
- To develop and evaluate a novel vaccine prototype against FIV-B.
- To assess the immunogenicity and viability of a recombinant MVA-based vaccine candidate.
Main Methods:
- Development of a modified vaccinia virus Ankara (MVA) vector expressing FIV-B envelope V1-V3 regions.
- Preclinical testing in C57BL/6 mice using a prime-boost immunization protocol.
- Evaluation of cellular (splenocyte proliferation, IFN-γ) and humoral (antibody) immune responses.
- Assessment of vaccine viability after lyophilization and storage.
Main Results:
- Immunization induced specific splenocyte proliferation upon stimulation with FIV-B peptides.
- Evidence of cellular and humoral immunity activation, including IFN-γ production and specific antibodies.
- The vaccine candidate demonstrated viability after lyophilization and storage, indicating potential for practical application.
Conclusions:
- The MVA/FIV-B vaccine prototype successfully elicited specific immune responses in a preclinical mouse model.
- The findings support further investigation and development of this vaccine for FIV-B prevention in cats.
- This study represents a significant step towards a much-needed FIV-B vaccine.
